but today, novavax said the fda is lifting those restrictions. the company says it's because it has proven that the vaccine did not cause that person's symptoms. novavax says it will resume late stage trials as quickly as possible. still ahead, we continue to honor all who served on this veterans day. that includes the more than a million americans who saw combat in vietnam. they spend time with one vet who is still dealing with the war. more than 50 years later. and i'm chief meteorologist jeff ranieri. i'll have updated looks at rain chances later bounced from one doctor to the next. did they even send my lab work...? wait, was i supposed to bring that? then there's the forms. the bills. the 'not a bills.' the.... ”press 4 to repeat these options.” [chaotic music] [inspirational music] healthcare can get a whole lot easier when your medical records, care and coverage are in one place. at kaiser permanente, all of us work together for all that is you. the impacts and effects don't ever really fade. nbc bay area's joe rosato jr. has the story of

i mean, look at novavax. i mean, the novavax vaccine took years to actually get the manufacturing processes to be able to produce that. so a lot of uncertainty. but i guess maybe as a leader, you sort of put the blinders on and charge ahead with just unflinching confidence that'll happen. i called paul mango. he said, don't worry, we were thinking about what would happen. but it's it it i think the company some of the reasons to believe we had a vaccine over referred to this on january 13th. so january 10th, a chinese researcher posted the genetic sequence for covid. we grabbed it on january 13th, the nih, niaid had actually developed a candidate vaccine. three days later, we had been working with madeira on i think it was a zika vaccine using this messenger rna platform. we talked to. them and said, because you can manufacture messenger rna a lot easier because it's a chemical synthesis, not a protein growth product. and we partnered with them eight weeks later. we were in the human clinic in human arms, nev

we are watching pfizer and novavax trading lower after donald trump said he was tabbing vaccine skepticobert f. kennedy, jr. to lead the department of health and human services. we are joined by a bloomberg reporter who covers that health care industry for us at bloomberg news. when you think about this nominee -- it is that, it is a nominee, still needs confirmation, we are seeing a significant reaction. how does that conflict for investors who were so excited about the pharma industry under president-elect trump? madison: it is like a reversal of the trend we saw after donald trump came ahead in the polls and won the election last week -- or two weeks ago, i am losing my mind. there was enthusiasm that m&a would pick up, trump would be better for the economy overall, which would be good for health care and pharma. with this nominee of rfk jr., that throws that into a little bit of a flux. he has been really critical about vaccines. he has walked back some of that criticism more recently and said he will not do away with vaccines entirely but he wants more information and once the stud

novavax said it would resume late-stage trials as soon as possible. kelly? >> pippa, thank you. stevens. >>> traffic to chatgpt is booming with the ceo sam altman bragging on x that it's the biggest website in the world with the site's incredible growth comes right as real concerns swirl over the real advancement of generative ai models is slowing down. deirdre bosa takes a closer look in today's tech check. >> in other words, how they peaked and that's a conversation gaining traction in silicon valley, the idea that rapid gen a.i. advancements are showing signs of deceleration and there was ben horowitz in the podcast. >> we are increasing gpus at the same rate, but we're not getting the intelligence improvements at all out of it. >> reed hoffmann made a similar point on another podcast and the information reporting that the increase in the quality of orion, that's open a.i.'s upcoming advance model is less than the quality jump between the last two flagship models gpt3 to gpt4, it peaked essentially because the models are running on data to train on. that could lead investors

look at novavax.ccine took years to get the manufacturing process to be able to produce of that. a lot of uncertainty but maybe as a leader you sort of put the blinders on and charge ahead with just unflinching conference that will happen. i called paul and he said we would think about what would happen. but i think some of the reasons, which had a vaccine on january 13. so genuine ten, a chinese researcher posted the genetic sequence for covid. we grabbed it. agenda with 13 the nih have developed a candidate vaccine three days later we've been working with moderna on i think a zika vaccine using this platform. we talked about and said said because you can manufacture messenger rna easy because it's a chemical synthesis not a protein growth product that we parted. eight weeks later we were in the human -- never before in history fastest time in eight weeks to be in the human clinic. and then we of course developed the others. that was a reason to believe. another reason to believe is it safe vaccine o

look at novavax, it took years get the manufacturing processes to be able to produce that. so a lot of uncertainty. i guess maybe as a leader you short of put the blinders on and charge ahead with just unflinching confidence it will happen. i called paul mango and he said, don't worry, we were thinking about what would happen. i think the combination -- some of the reasons to believe, we had a vaccine on january 13. so january 10, a chinese researcher posted the genetic sequence for covid. we grabbed it. january 13, the n.i.h., niid had developed candidate vaccine three days later. we had been working with moderna, i think it was a zika vaccine using this messenger r.n.a. platform. we talked to them and said can you manufacture messenger r.n.a. easier because it's a chemical synthesis not a protein growth product. we partnered with them. eight weeks later we were in human arms. eight weeks to be in human clinic. then we of course developed all the others. that was a reason to believe. another reason to believe is, it's a vaccinable target. so you know, no -- hiv-aids was th

pfizer and moderna and gsk and astrazeneca and novavax. thing is carrying through to this morning. you are seeing the extended hours trade where there are still losses, more modest than yesterday, but a bit of a follow through. let's bring in javers on the president-elect's choice for hhs and what exactly can you tell us about whether or not we could see a path forward that is smooth for his irmation and the policies that rfk jr could have in his initial hypothetical months on the job? >> reporter: boy, john, dom, that is a big question the confirmation hearing is a big one if we have one you mentioned the vaccine stocks it is more than the vaccine stocks impacted here because this is a huge agency. hhs has a budget of $1.6 trillion they oversee the national institute of health and cdc and the fda, the food and drug administration, which has approvals over food products and all chemicals and a whole range of things in the food industry that rfk jr talked about in the past that could be impacted. you look at con-agra that moved on the news

lori is looking at the movers, you have to start with novavax. >> upon present fda lifted the hold onheir combo covid and flu shot, there has been a safety concern and whether the patient's experience nerve cell damage but that's been unrelated to the vaccine. >> i want to know how would people want the kickboxing covid and flu shot how many people go out and get it. >> older americans. >> with pre-existing conditions. i don't know anybody. >> we go to the doctor's office all the time and i get the flu shot and the doctor is like today wanted covid shot and i'm like literally been asked i think all the parents are saying no. >> this is an interesting company the electric air taxes. the stock is up 6% the first right outside of the united states happened in japan toyota is a backer to the company what would've been a two hour drive by car on the roads was 25 minutes in the electric air taxi. not bad. it winds signed a deal with stadium. >> sophia stadium one of the largest in the nfl home of the rams and the chargers the second level club called the east owners club will be named. >> y

shares in pfizer, novavax and biontech down 3 to 5% as well.is contributing to a drop for the major market indexes as well as we take a live look. the dow jones down about 300 points, as it seems that post-election rally kind of losing some steam there. down three quarters of a percent. the s&p 500 down more than one full percentage point there 5880. and the nasdaq down almost 2%, 368 points. on the downside, for the nasdaq, down even more than the dow. number wise, facebook's parent company is appealing a ruling that says social media companies can be sued by schools and states over addiction. now, a federal judge in oakland ruled last month that meta google, tiktok and snap can face lawsuits that claim the apps are addicting and contributing to a mental health crisis. now, meta has filed in federal appeals court to try to block that. 34 state attorneys general have filed claims against meta, which owns facebook and instagram. the new trump administration reportedly planning to end the $7,500 tax credit for electric vehicles. according to reut

stuart: novavax? >> the sales forecast is declining based on slowing covid trends.ers fall. stuart: i'm not surprised at slowing covid trends. when who gets a vaccine these days? shopify, put them back on, please. whoa, they did well. >> surging. this solidifies the trend of people continuing to go online. they're also a signing with big box retailers like toys r us, so trying to do volume instead of the mom and pop seller. stuart source how about tyson foods? >> chicken is doing better as consumers continue to trade down from beef. chicken is the second largest source of revenue for the company, so it's doing well for them. stuart toort another one that's up nicely. live nation, i know they posted their earns after the summer concert season. they did okay. >> they said this was their strongest concert season ever, and it's only going to get bigger in 2025 because you have shakira and coldplay coming, get excited. stuart: coldplay is an exciting band, i believe? [laughter] >> to some. stuart: the prices they ask is astronomical. >> it is. but people are willing to s

novavax, my apologies. revenue, 700 million dollars, that originally was $800 million.to two honey 25 that is incrementally below the original guidance. annmarie: so some movers ahead of the market open. investors eyeing the data including cpi, ppi and retail sales was a ton of fence with thursday being the big one piece is we are going to hear from fed chair jay powell himself. joining us now, sonia, thanks for joining us around the table. faced with data this week, what i you looking at? >> we are looking at cpi. inflation still matters, politics obviously front and center. but with cpi specifically, we expect some stickiness in the sector of used vehicle prices, and that should persist into the year-end and probably into the first quarter of next year. then there are some seasonal factors. that is something to keep in mind at the fed kind of navigates this rather new environment. dani: over the weekend we heard from neel kashkari who said we want to make sure inflation is vanquished. a bit of a difference from when he said the labor market is our first and top concer